Rescue Tirofiban for Early Neurological Deterioration After Tenecteplase in Capsular Warning Syndrome Authors: Claudia Cuccurullo, Antonio De Mase, Paolo Candelaresi, Vincenzo Andreone Published: 2026 Dear Editor, Capsular warning syndrome (CWS) consists of recurrent episodes of focal neurological deficits, occurring at least three times within 24 hours, and attributed to incipient ischemia in the internal capsule.1 Several mechanisms have been proposed, including hemodynamic instability, progressive branch-artery atheromatous disease, and thrombosis of penetrating vessels. Clinically, CWS is relevant because it carries a high risk of progression to capsular infarction.2 Clinical management aims to prevent permanent ischemic injury, although the optimal strategy remains uncertain. We report a 47-year-old left-handed Caucasian man, with history of heavy smoking, who presented to our emergency department with fluctuating left hemiparesis that had started one hour earlier. His past medical history was otherwise unremarkable, and he was not on antiplatelet therapy. On admission, neurological examination revealed left hemiparesis predominantly affecting the upper limb and mild dysarthria (NIHSS [National Institutes of Health Stroke Scale] score: 8). Blood pressure was 130/80 mm Hg, and blood glucose was 105 mg/dL. Brain CT was unremarkable (Fig. 1), and CT angiography showed no large-vessel occlusion or significant extra- or intra-cranial atherosclerosis. Tenecteplase (TNK) at a dose of 0.25 mg/kg was administered 15 minutes after admission. During the following hours, multiple episodes of fluctuating left hemiparesis persisted, alternating between severe weakness and recovery. Blood pressure remained stable throughout, while the patient was monitored in the Stroke Unit. Four hours after TNK administration, neurological fluctuations ceased, leaving a persistent severe left hemiparesis. Hemodynamic support with plasma expanders was attempted, without clinical benefit. After one hour without improvement, repeat brain CT excluded hemorrhagic complications. Because a disabling deficit persisted despite intravenous thrombolysis (IVT) and no large-vessel occlusion was identified, platelet-mediated thrombosis of penetrating arteries was suspected. Rescue tirofiban was therefore initiated five hours after IVT, following informed consent, as a continuous intravenous infusion (0.4 µg/kg/min for 30 minutes, followed by 0.1 µg/kg/min for 23.5 hours). Concomitantly with completion of the loading dose, the patient improved to mild left facial paresis, slight dysarthria, and left upper limb clumsiness without weakness (NIHSS score: 3). Importantly, no further neurological fluctuations occurred, and progressive clinical improvement was observed, without hemorrhagic complications. Four hours before tirofiban discontinuation, dual antiplatelet therapy with clopidogrel (300 mg loading dose) and aspirin 100 mg was initiated. Brain MRI performed 48 hours after symptom onset revealed a recent small subcortical infarction in the right internal capsule (Fig. 1 and Supplementary Fig. 1 in the online-only Data Supplement). The patient achieved complete clinical recovery, with a 90-day modified Rankin Scale score of 0. CWS represents a high-risk clinical condition that may rapidly progress to permanent disabling stroke. It may occur in up to 20%–36% of patients with lacunar syndromes, within hours to days after symptom onset.123 However, its optimal management remains uncertain.3 IVT is recommended in eligible patients with acute lacunar stroke,34 but evidence supporting its effectiveness in preventing neurological fluctuation and early neurological deterioration (END) in CWS is limited.23 Indeed, IVT alone may be insufficient to counteract disease progression related to platelet-mediated thrombosis of branch-arteries and penetrating vessels.24 Current guidelines discourage antiplatelet therapy within 24 hours after IVT; however, this recommendation largely derives from studies evaluating early aspirin administration rather than more targeted antiplatelet agents.45 In this context, glycoprotein IIb/IIIa inhibitors such as tirofiban have emerged as potential therapeutic options. Recent randomized clinical trials suggest that tirofiban may reduce the risk of END in patients with non-cardioembolic stroke, including those receiving IVT and not eligible for endovascular thrombectomy (e.g., RESCUE-BT2, TREND, ASSET-IT).678 Notably, RESCUE-BT2 demonstrated benefit in patients without large or medium vessel occlusion, in whom penetrating artery disease is often the presumed mechanism. In the present case, TNK was administered during the fluctuation phase, but failed to prevent progression to a persistent neurological deficit. Neurological stabilization occurred shortly after initiation of tirofiban, with subsequent sustained clinical recovery. However, this temporal association does not allow causal inference and should be interpreted with caution. Several alternative explanations should be considered. A synergistic or delayed thrombolytic effect of TNK cannot be excluded, given its distinct pharmacokinetic and pharmacodynamic properties, including longer half-life and greater fibrin specificity. Moreover, spontaneous stabilization, hemodynamic factors, or the intrinsic fluctuation pattern of CWS may also have contributed to the observed clinical improvement. The presence of a small subcortical infarction on follow-up imaging further supports the need for cautious interpretation. Evidence regarding tirofiban administration after TNK remains limited, as most available data involve alteplase.78 Consequently, the effect and safety of early combination therapy with antiplatelet agents after TNK are less well established. Reports on tirofiban use specifically in CWS are also scarce.910 To our knowledge, this is the first report describing rescue tirofiban infusion after TNK failure in CWS. Although limited by its single-case design, the close temporal association between tirofiban initiation and neurological stabilization is noteworthy. This observation supports the hypothesis that platelet-mediated mechanisms may contribute to END after IVT in CWS and suggests a potential therapeutic window between thrombolysis failure and guideline-restricted antiplatelet initiation. Further prospective studies are needed to clarify the safety, optimal timing, and efficacy of tirofiban in this setting.